However, the place of PARPi in patients with endocrine-receptor positive, HER2 negative (ER+/HER2-) breast cancer has been less clearly defined due to the lower relative frequency of BRCA1/2 PV (~5%) along with more effective lines of treatments available. Here, ERBB2 is linked to breast carcinoma.